Astrazeneca PLC (AZN) : Traders are bullish on Astrazeneca PLC (AZN) as it has outperformed the S&P 500 by a wide margin of 7.39% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.09%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.06% in the last 1 week, and is up 7.81% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
AstraZeneca PLC is up 18.54% in the last 3-month period. Year-to-Date the stock performance stands at 3.41%. The stock has recorded a 20-day Moving Average of 1.41% and the 50-Day Moving Average is 9.79%.
Astrazeneca PLC (NYSE:AZN): The stock opened at $33.53 on Friday but the bulls could not build on the opening and the stock topped out at $33.57 for the day. The stock traded down to $33.31 during the day, due to lack of any buying support eventually closed down at $33.56 with a loss of -0.03% for the day. The stock had closed at $33.57 on the previous day. The total traded volume was 3,266,344 shares.
Also, Argus Research initiates coverage on Astrazeneca PLC (NYSE:AZN) . Analysts at the Argus Research have a current rating of Hold on the shares. The rating by the firm was issued on July 12, 2016.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).